Why Harvard Bioscience Is Poised to Pop
Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, medical instruments maker Harvard Bioscience has earned a coveted five-star ranking.
With that in mind, let's take a closer look at Harvard Bioscience and see what CAPS investors are saying about the stock right now.
Harvard Biosciencefacts
Headquarters (founded) | Holliston, Mass. (1901) |
Market Cap | $132.3 million |
Industry | Life sciences tools and services |
Trailing-12-Month Revenue | $112.0 million |
Management | Chairman/CEO Chane Graziano |
Return on Equity (average, past 3 years) | 11.1% |
Cash/Debt | $20.3 million / $15.3 million |
Competitors | Becton Dickinson |
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 96% of the 166 members who have rated Harvard Bioscience believe the stock will outperform the S&P 500 going forward.
This past weekend, one of those bulls, All-Star TMFDeej, helped bring the special opportunity to our community's attention:
Harvard Bioscience is in the process of spinning off its money-losing HART division, leaving behind a manufacturer of scientific instruments trading for only three times earnings, yet growing at 15% to 20% per year. See Jim Royal's great article on the situation for more information.
If you want to retire rich, you need to put together the best portfolio you can. Of course, despite its five-star rating, Harvard Bioscience may not be your top choice.
We've found another growth play we are incredibly excited about -- excited enough to dub it "The Only Stock You Need to Profit from the NEW Technology Revolution." We have compiled a special free report for investors to uncover this stock today. The report is 100% free, but it won't be here forever, so click here to access it now.
Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.
The article Why Harvard Bioscience Is Poised to Pop originally appeared on Fool.com.
Fool contributor Brian Pacampara has no position in any stocks mentioned. The Motley Fool recommends Becton Dickinson and Thermo Fisher Scientific. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.
